Immunoconjugates targeting HER2
US11400164B2 · kind B2 · utility
0Cited by
146References
44Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Sep 2, 2021 |
| Grant date | Aug 2, 2022 |
| Priority date | — |
| Expiry date | Sep 2, 2041 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P35/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention provides an immunoconjugate of formula: or pharmaceutically acceptable salt thereof, wherein subscript r is an integer from 1 to 10, subscript n is an integer from about 2 to about 25, and “Ab” is an antibody construct that has an antigen binding domain that binds HER2. The invention further provides compositions comprising and methods of treating cancer with the immunoconjugate.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.